• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Aethlon Medical Inc.

    2/14/25 1:21:10 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care
    Get the next $AEMD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Aethlon Medical, Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)


    00808Y406

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00808Y406


    1Names of Reporting Persons

    Ikarian Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,229,285.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,229,285.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,229,285.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.7 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, 9, and 11 represent shares of common stock, $0.001 par value per share ("Common Stock") of Aethlon Medical, Inc. (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 14,114,096 shares of Common Stock of the Issuer outstanding as of January 30, 2025, as disclosed in the Issuer's Regulation A Offering Statement filed with the U.S. Securities and Exchange Commission (the "SEC") on January 30, 2025.


    SCHEDULE 13G

    CUSIP No.
    00808Y406


    1Names of Reporting Persons

    Neil Shahrestani
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,229,285.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,229,285.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,229,285.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.7 %
    12Type of Reporting Person (See Instructions)

    IN, HC

    Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, 9, and 11 represent shares of Common Stock of the Issuer held by the Fund and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 14,114,096 shares of Common Stock of the Issuer outstanding as of January 30, 2025, as disclosed in the Issuer's Regulation A Offering Statement filed with the SEC on January 30, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Aethlon Medical, Inc.
    (b)Address of issuer's principal executive offices:

    11555 Sorrento Valley Road, Suite 203, San Diego, California
    Item 2. 
    (a)Name of person filing:

    This statement is filed jointly by and on behalf of each of Ikarian Capital, LLC, a Delaware limited liability company ("Ikarian Capital"), and Neil Shahrestani (together referred herein as the "Reporting Persons"). The Fund, and certain separately managed accounts managed by Ikarian Capital (collectively, the "Managed Accounts"), are the record owners of the securities covered by this statement. Ikarian Capital is an investment adviser registered under the Investment Advisers Act of 1940, as amended, and serves as investment manager to the Fund and as sub-adviser to the Managed Accounts, and may be deemed to have beneficial ownership of the securities covered by this statement through the investment discretion it has over the Fund and the Managed Accounts. Ikarian Capital is ultimately controlled, indirectly, by Mr. Shahrestani. Accordingly, Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by Ikarian Capital. The Fund disclaims beneficial ownership of the shares held by the Managed Accounts. The Managed Accounts disclaim beneficial ownership of the shares held by the Fund. Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement. Each Reporting Person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer or (ii) a member of any group with respect to the issuer or any securities of the issuer.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is c/o Ikarian Capital, LLC, 100 Crescent Court, Suite 1620, Dallas, Texas 75201.
    (c)Citizenship:

    See Item 4 on the cover page(s) hereto
    (d)Title of class of securities:

    Common Stock, $0.001 par value per share
    (e)CUSIP No.:

    00808Y406
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Item 9 on the cover pages(s) hereto.
    (b)Percent of class:

    See Item 11 on the cover page(s) hereto.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Item 5 on the cover page(s) hereto.

     (ii) Shared power to vote or to direct the vote:

    See Item 6 on the cover page(s) hereto.

     (iii) Sole power to dispose or to direct the disposition of:

    See Item 7 on the cover page(s) hereto.

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 8 on the cover page(s) hereto.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The information set forth in Item 2(a) is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Ikarian Capital, LLC
     
    Signature:/s/ Neil Shahrestani
    Name/Title:Neil Shahrestani, Sole Manager
    Date:02/14/2025
     
    Neil Shahrestani
     
    Signature:/s/Neil Shahrestani
    Name/Title:Neil Shahrestani
    Date:02/14/2025
    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD

    DatePrice TargetRatingAnalyst
    7/7/2025$1.50Neutral
    H.C. Wainwright
    6/25/2021$5.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AEMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gikakis Nicolas covered exercise/tax liability with 1,786 shares, decreasing direct ownership by 7% to 22,683 units (SEC Form 4)

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    10/2/25 4:15:05 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Director Broenniman Edward G covered exercise/tax liability with 893 shares, decreasing direct ownership by 3% to 25,397 units (SEC Form 4)

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    10/2/25 4:15:03 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Director Shah Chetan covered exercise/tax liability with 1,786 shares, decreasing direct ownership by 7% to 22,672 units (SEC Form 4)

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    10/2/25 4:15:06 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    SEC Filings

    View All

    SEC Form 10-Q filed by Aethlon Medical Inc.

    10-Q - AETHLON MEDICAL INC (0000882291) (Filer)

    11/12/25 5:10:42 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    11/12/25 4:16:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Inc. filed SEC Form 8-K: Other Events

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    11/6/25 9:15:28 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million

    SAN DIEGO, Dec. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 595,897 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 1,042,820 shares of common stock, in a private placement priced at-the-market under Nasdaq rules. The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying wa

    12/5/25 9:15:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs

    Results Support the Further Investigation of the Hemopurifier in Long COVID SAN DIEGO, Dec. 2, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced today the 20 November 2025 publication of a pre-clinical study entitled "Increased mannosylation of extracellular vesicles in Long COVID plasma provides a potential therapeutic target for Galanthus nivalis agglutinin (GNA) affinity resin" in the pre-print online archive bioRxiv: https://www.biorxiv.org/cgi/content/short/2025.11.21.689519v1. This paper has simultaneously been submitted for consideration to a peer-re

    12/2/25 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

    Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Compliance matters resolved, Aethlon remains in good standing with Nasdaq.Clinical Progress: Recruitment underway for Cohort 2 of the Australian oncology trial under amended protoc

    11/12/25 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Aethlon Medical with a new price target

    H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50

    7/7/25 8:15:50 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Aethlon Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Aethlon Medical with a rating of Buy and set a new price target of $9.00 from $5.00 previously

    6/25/21 6:10:29 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. initiated coverage on Aethlon Medical with a new price target

    HC Wainwright & Co. initiated coverage of Aethlon Medical with a rating of Buy and set a new price target of $5.00

    6/1/21 8:48:18 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Financials

    Live finance-specific insights

    View All

    Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

    Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Compliance matters resolved, Aethlon remains in good standing with Nasdaq.Clinical Progress: Recruitment underway for Cohort 2 of the Australian oncology trial under amended protoc

    11/12/25 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025

    SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2025, at 4:15 p.m. ET on Wednesday, November 12, 2025. Management will host a conference call on Wednesday, November 12, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10204579/

    11/7/25 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update

    Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Operating Expenses Cut by 32% Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2025, and provided an update on recent developments.  Key First Quarter Highlights First Cohort Complete in Australian Hemopurifier® cancer trial — all patients treated without device-related serious

    8/13/25 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aethlon Medical, Inc. (Amendment)

    SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

    1/13/22 10:30:14 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Aethlon Medical, Inc.

    SC 13G - AETHLON MEDICAL INC (0000882291) (Subject)

    6/15/21 10:01:32 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

    2/22/21 9:53:48 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care